Ubaid Khan, Ahmed Mazen Amin, Amira Mohamed Taha, Yehya Khlidj, Majd M AlBarakat, Mariam Elewidi, Mohamed Abuelazm, Mustafa Turkmani, Basel Abdelazeem, Rida Laeeq
{"title":"钠-葡萄糖共转运蛋白2抑制剂对急性心肌梗死后临床结局的影响：随机对照试验的系统回顾和荟萃分析","authors":"Ubaid Khan, Ahmed Mazen Amin, Amira Mohamed Taha, Yehya Khlidj, Majd M AlBarakat, Mariam Elewidi, Mohamed Abuelazm, Mustafa Turkmani, Basel Abdelazeem, Rida Laeeq","doi":"10.1080/14796678.2025.2464449","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce cardiovascular events, especially in diabetic patients. However, the cardioprotective effects of early SGLT2i administration following acute myocardial infarction (AMI) remain unclear.</p><p><strong>Objective: </strong>This study aims to investigate the impact of SGLT2is on clinical outcomes in patients post-AMI.</p><p><strong>Methods: </strong>A comprehensive search was conducted in PubMed, CENTRAL, WOS, Scopus, and EMBASE up to April 2024. Risk ratio (RR) was used for dichotomous outcomes and mean difference (MD) for continuous outcomes, with 95% confidence intervals (CI).</p><p><strong>Results: </strong>Seven studies with 11,407 patients were included. SGLT2is did not significantly reduce the incidence of major adverse cardiovascular events (MACE) (RR = 0.94, 95% CI [0.68, 1.29], <i>p</i> = 0.69), all-cause mortality (RR = 1.01, 95% CI [0.84, 1.21], <i>p</i> = 0.93), or stroke (RR = 0.61, 95% CI [0.29,1.28], <i>p</i> = 0.19). However, SGLT2is significantly reduced the risk of heart failure (RR = 0.76, 95% CI [0.63, 0.91], <i>p</i> < 0.01) and improved left ventricular ejection fraction (MD = 1.86, 95% CI [1.58, 2.14], <i>p</i> < 0.01).</p><p><strong>Conclusion: </strong>In post-AMI patients, SGLT2is do not significantly affect MACE or mortality but are associated with reduced heart failure risk and improved ejection fraction.</p><p><strong>Protocol registration: </strong>PROSPERO identifier number: CRD42024506806.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"177-190"},"PeriodicalIF":1.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11875467/pdf/","citationCount":"0","resultStr":"{\"title\":\"The effect of sodium-glucose co-transporter 2 inhibitors on clinical outcomes after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.\",\"authors\":\"Ubaid Khan, Ahmed Mazen Amin, Amira Mohamed Taha, Yehya Khlidj, Majd M AlBarakat, Mariam Elewidi, Mohamed Abuelazm, Mustafa Turkmani, Basel Abdelazeem, Rida Laeeq\",\"doi\":\"10.1080/14796678.2025.2464449\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce cardiovascular events, especially in diabetic patients. However, the cardioprotective effects of early SGLT2i administration following acute myocardial infarction (AMI) remain unclear.</p><p><strong>Objective: </strong>This study aims to investigate the impact of SGLT2is on clinical outcomes in patients post-AMI.</p><p><strong>Methods: </strong>A comprehensive search was conducted in PubMed, CENTRAL, WOS, Scopus, and EMBASE up to April 2024. Risk ratio (RR) was used for dichotomous outcomes and mean difference (MD) for continuous outcomes, with 95% confidence intervals (CI).</p><p><strong>Results: </strong>Seven studies with 11,407 patients were included. SGLT2is did not significantly reduce the incidence of major adverse cardiovascular events (MACE) (RR = 0.94, 95% CI [0.68, 1.29], <i>p</i> = 0.69), all-cause mortality (RR = 1.01, 95% CI [0.84, 1.21], <i>p</i> = 0.93), or stroke (RR = 0.61, 95% CI [0.29,1.28], <i>p</i> = 0.19). However, SGLT2is significantly reduced the risk of heart failure (RR = 0.76, 95% CI [0.63, 0.91], <i>p</i> < 0.01) and improved left ventricular ejection fraction (MD = 1.86, 95% CI [1.58, 2.14], <i>p</i> < 0.01).</p><p><strong>Conclusion: </strong>In post-AMI patients, SGLT2is do not significantly affect MACE or mortality but are associated with reduced heart failure risk and improved ejection fraction.</p><p><strong>Protocol registration: </strong>PROSPERO identifier number: CRD42024506806.</p>\",\"PeriodicalId\":12589,\"journal\":{\"name\":\"Future cardiology\",\"volume\":\" \",\"pages\":\"177-190\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11875467/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future cardiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/14796678.2025.2464449\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14796678.2025.2464449","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
钠-葡萄糖共转运蛋白2抑制剂（SGLT2is）可减少心血管事件，尤其是糖尿病患者。然而，急性心肌梗死（AMI）后早期给药SGLT2i的心脏保护作用尚不清楚。目的：本研究旨在探讨SGLT2is对ami后患者临床结局的影响。方法：综合检索截至2024年4月的PubMed、CENTRAL、WOS、Scopus和EMBASE数据库。二分类结局采用风险比（RR），连续结局采用均值差（MD），置信区间为95%。结果：纳入7项研究，11,407例患者。SGLT2is并没有显著降低主要不良心血管事件（MACE） （RR = 0.94, 95% CI [0.68, 1.29], p = 0.69）、全因死亡率（RR = 1.01, 95% CI [0.84, 1.21], p = 0.93）或卒中（RR = 0.61, 95% CI [0.29,1.28], p = 0.19）的发生率。然而，sglt2i可显著降低心衰风险（RR = 0.76, 95% CI [0.63, 0.91], p）。结论：在ami后患者中，sglt2i对MACE或死亡率没有显著影响，但与心衰风险降低和射血分数改善相关。协议注册：PROSPERO标识号：CRD42024506806。
The effect of sodium-glucose co-transporter 2 inhibitors on clinical outcomes after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.
Introduction: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce cardiovascular events, especially in diabetic patients. However, the cardioprotective effects of early SGLT2i administration following acute myocardial infarction (AMI) remain unclear.
Objective: This study aims to investigate the impact of SGLT2is on clinical outcomes in patients post-AMI.
Methods: A comprehensive search was conducted in PubMed, CENTRAL, WOS, Scopus, and EMBASE up to April 2024. Risk ratio (RR) was used for dichotomous outcomes and mean difference (MD) for continuous outcomes, with 95% confidence intervals (CI).
Results: Seven studies with 11,407 patients were included. SGLT2is did not significantly reduce the incidence of major adverse cardiovascular events (MACE) (RR = 0.94, 95% CI [0.68, 1.29], p = 0.69), all-cause mortality (RR = 1.01, 95% CI [0.84, 1.21], p = 0.93), or stroke (RR = 0.61, 95% CI [0.29,1.28], p = 0.19). However, SGLT2is significantly reduced the risk of heart failure (RR = 0.76, 95% CI [0.63, 0.91], p < 0.01) and improved left ventricular ejection fraction (MD = 1.86, 95% CI [1.58, 2.14], p < 0.01).
Conclusion: In post-AMI patients, SGLT2is do not significantly affect MACE or mortality but are associated with reduced heart failure risk and improved ejection fraction.
期刊介绍：
Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
